BR112023005832A2 - Forma cristalina de tegavivint, método de preparação e uso da mesma - Google Patents
Forma cristalina de tegavivint, método de preparação e uso da mesmaInfo
- Publication number
- BR112023005832A2 BR112023005832A2 BR112023005832A BR112023005832A BR112023005832A2 BR 112023005832 A2 BR112023005832 A2 BR 112023005832A2 BR 112023005832 A BR112023005832 A BR 112023005832A BR 112023005832 A BR112023005832 A BR 112023005832A BR 112023005832 A2 BR112023005832 A2 BR 112023005832A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline form
- tegavivint
- preparation
- crystalline
- dimethylpiperidin
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- OMWCXCBGEFHCTN-FGYAAKKASA-N N-[3,6-bis[[(3R,5S)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine Chemical compound C1[C@@H](C)C[C@@H](C)CN1S(=O)(=O)C1=CC=C(C(NO)=C2C(C=C(C=C2)S(=O)(=O)N2C[C@H](C)C[C@H](C)C2)=C2N=O)C2=C1 OMWCXCBGEFHCTN-FGYAAKKASA-N 0.000 title abstract 2
- 229940121335 tegavivint Drugs 0.000 title abstract 2
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
FORMA CRISTALINA DE TEGAVIVINT, MÉTODO DE PREPARAÇÃO E USO DA MESMA. A presente invenção se refere a formas cristalinas de (9E,10E)-2,7-bis((3,5-dimetilpiperidin-1-il)sulfonil)antraceno-9,10-diona dioxima, composições farmacêuticas que compreendem a forma cristalina, processos para preparar a forma cristalina e métodos de uso para os mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/037,287 US11136307B1 (en) | 2020-09-29 | 2020-09-29 | Crystalline form of tegavivint, method of preparation, and use thereof |
| PCT/US2021/052610 WO2022072470A1 (en) | 2020-09-29 | 2021-09-29 | Crystalline form of tegavivint, method of preparation, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023005832A2 true BR112023005832A2 (pt) | 2023-05-02 |
Family
ID=77923652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023005832A BR112023005832A2 (pt) | 2020-09-29 | 2021-09-29 | Forma cristalina de tegavivint, método de preparação e uso da mesma |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11136307B1 (pt) |
| EP (1) | EP4222148A1 (pt) |
| JP (1) | JP2023543055A (pt) |
| KR (1) | KR20230145030A (pt) |
| CN (1) | CN116323586A (pt) |
| BR (1) | BR112023005832A2 (pt) |
| CA (1) | CA3193404A1 (pt) |
| IL (1) | IL301748A (pt) |
| MX (1) | MX2023003652A (pt) |
| WO (1) | WO2022072470A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11136307B1 (en) * | 2020-09-29 | 2021-10-05 | Iterion Therapeutics, Inc. | Crystalline form of tegavivint, method of preparation, and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108314663B (zh) * | 2007-05-10 | 2022-05-13 | 多格伍德药品公司 | 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途 |
| EA022290B1 (ru) * | 2008-11-21 | 2015-12-30 | Форест Лэборетериз Холдингз Лимитед | Антрахинондиоксимы и их применение |
| US9963475B2 (en) * | 2015-07-28 | 2018-05-08 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compound prodrugs and their uses |
| WO2018223023A1 (en) * | 2017-06-02 | 2018-12-06 | Beta Cat Pharmaceuticals, Inc. | Methods for treatment of fibrotic diseases |
| WO2019099836A1 (en) * | 2017-11-16 | 2019-05-23 | Northwestern University | Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases |
| EP3810118A4 (en) * | 2018-06-01 | 2022-03-30 | Iterion Therapeutics, Inc. | FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS |
| US11136307B1 (en) * | 2020-09-29 | 2021-10-05 | Iterion Therapeutics, Inc. | Crystalline form of tegavivint, method of preparation, and use thereof |
-
2020
- 2020-09-29 US US17/037,287 patent/US11136307B1/en active Active
-
2021
- 2021-09-29 BR BR112023005832A patent/BR112023005832A2/pt unknown
- 2021-09-29 WO PCT/US2021/052610 patent/WO2022072470A1/en unknown
- 2021-09-29 US US17/489,684 patent/US20220098173A1/en active Pending
- 2021-09-29 IL IL301748A patent/IL301748A/en unknown
- 2021-09-29 MX MX2023003652A patent/MX2023003652A/es unknown
- 2021-09-29 EP EP21876377.9A patent/EP4222148A1/en active Pending
- 2021-09-29 CA CA3193404A patent/CA3193404A1/en active Pending
- 2021-09-29 JP JP2023519457A patent/JP2023543055A/ja active Pending
- 2021-09-29 KR KR1020237014458A patent/KR20230145030A/ko unknown
- 2021-09-29 CN CN202180066982.2A patent/CN116323586A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220098173A1 (en) | 2022-03-31 |
| WO2022072470A1 (en) | 2022-04-07 |
| MX2023003652A (es) | 2023-06-01 |
| CN116323586A (zh) | 2023-06-23 |
| KR20230145030A (ko) | 2023-10-17 |
| US11136307B1 (en) | 2021-10-05 |
| JP2023543055A (ja) | 2023-10-12 |
| EP4222148A1 (en) | 2023-08-09 |
| IL301748A (en) | 2023-05-01 |
| CA3193404A1 (en) | 2022-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000201A (es) | Compuestos heteroaril tetracíclicos | |
| CO2021012381A2 (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| CO7170182A2 (es) | Derivados de 2,2-difluoropropinamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos | |
| CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| BR112017023740A2 (pt) | ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida? | |
| CL2021002963A1 (es) | Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer | |
| CO2020007018A2 (es) | Proceso para preparar tapinarof | |
| BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
| BR112023005832A2 (pt) | Forma cristalina de tegavivint, método de preparação e uso da mesma | |
| BR112018073017A2 (pt) | formas cristalinas de crisaborol na forma livre e método de preparação e uso das mesmas | |
| CU20120137A7 (es) | Hidrato del hidrocloruro de agomelatina y preparación de éste | |
| BR112018072755A2 (pt) | composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica | |
| BR112014001083B8 (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto | |
| PE20211243A1 (es) | Procedimiento y productos intermedios para la preparacion de bilastina | |
| AR120057A1 (es) | Composiciones neoantigénicas y usos de estas | |
| CO2024013531A2 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| CR20190379A (es) | Moduladores del receptor de estrógeno | |
| CO2022003769A2 (es) | Proceso industrial para la preparación de estetrol de alta pureza | |
| CL2024000373A1 (es) | Compuesto inductor de la degradación de plk1 novedoso | |
| CO2024002844A2 (es) | Compuestos espirocíclicos | |
| BR112022020953A2 (pt) | Formulação à base de laminarina para aplicações agrícolas | |
| CO2022001218A2 (es) | Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso | |
| CL2021001511A1 (es) | Novedosa psicosa-6-fosfato fosfatasa, composición para la producción de psicosa que comprende la misma y procedimiento para la producción de psicosa mediante el uso de la misma | |
| CL2024001565A1 (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso. | |
| BR112022016044A2 (pt) | Processo para preparação de compostos artropodicidas de antranilamida |